CTOs on the Move

St. John`s Episcopal Hospital

www.ehs.org

 
Episcopal Health Services (EHS) traces its roots almost 150 years back to the Church Charity Foundation which was founded on February 6, 1851 for aged indigent persons and for the welfare of orphans, half orphans, and other destitute children.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.ehs.org
  • 327 Beach 19th Street
    Far Rockaway, NY USA 11691
  • Phone: 718.869.7000

Executives

Name Title Contact Details

Similar Companies

St. Mary Medical Center Foundation

St. Mary Medical Center Foundation is a Langhorne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Workit Health

Workit Health offers online, on-demand evidence-based addiction treatment. Through our mobile and web apps, members meet with clinicians, counselors, and coaches and work towards self-set recovery goals. Our interactive curriculum of over 800 engaging online courses about addiction keep members on track in the comfort of home. We offer 24/7 recovery that fits into daily life, designed by experts.

Gaiam, Inc.

Gaiam, Inc. (Gaiam) is a lifestyle media company providing a selection of information, media, products and services to customers, who value personal development, wellness, ecological lifestyles, responsible media and conscious community.

MD Care Inc

MD Care Inc is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.